OtherOTC:BVAXF

BioVaxys Further Expands Intellectual Property Portfolio in Global Markets

- Files Applications for International Patent and Trademark Protection of CoviDTH VANCOUVER, BC, Oct. 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has broadened the patent coverage on CoviDTH, its T ...

2021-10-28 20:00 1320

BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine

VANCOUVER, BC, Oct. 20, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has filed with the United States Patent & Trademark Office ("USPTO") a provisional patent application for its haptenized viral antigen va...

2021-10-20 21:24 2807

BioVaxys Begins Toxicity Study Ahead of CoviDTH IND Submission

VANCOUVER, BC, Sept. 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF)("BioVaxys" or "Company"), announced today that it has started its plannedin vivo animal toxicology study of CoviDTH in parallel with the preparation of an IND submission. Under the terms ...

2021-09-28 20:00 4991

BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins

- Potential for superior tolerability to mRNA and Adenovirus Vector vaccines - Production Agreement signed with Millipore-Sigma for SARS-CoV-2 Vaccine Supply VANCOUVER, BC, Sept. 23, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), a...

2021-09-23 15:00 3959

BioVaxys Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction Milestone

VANCOUVER, British Columbia, Sept. 17, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), announced today that cancer vaccine manufacturing partner Bio Elpida inLyon, France, has reached major milestones in the development of the bioproduction proce...

2021-09-17 15:00 3418

BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH Programs

VANCOUVER, BC, Sept. 14, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), announced today that global CDMO partner WuXi Biologics, has completed the synthesis of recombinant SARS-CoV-2 s-protein for BVX-0320, the company's COVID-19 vaccine candida...

2021-09-14 15:00 3739

Further Study in humans shows that the DTH response, the basis for CoviDTH, is highly durable and persists for at least one year after COVID-19 exposure or vaccine administration

VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Sept. 7, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that the Scientific Advisor for its CoviDTH program,Yvelise Barrios, MD, PhD, and Clinical Immuno...

2021-09-07 20:00 4638

Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans

Yvelise Barrios, MD, PhD, Immunologist and leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behindCoviDTH, joins BioVaxys as scientific adviser VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Aug. 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (C...

2021-08-03 20:00 3647

FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH

VANCOUVER, British Columbia, July 22, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTCQB: BVAXF)("BioVaxys"), is pleased to announce today that the US Food and Drug Administration ("FDA") has provided its official Written Response to the Company's request for a Pre-IN...

2021-07-22 21:50 7818

BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development

VANCOUVER, British Columbia, June 15, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF)("BioVaxys"), is pleased to announce today that the US Food and Drug Administration (FDA) has reviewed its Pre-IND request for a Type B review of its CoviDTH program and has d...

2021-06-15 04:19 13484

BioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine Study

VANCOUVER, BC and LYON, France, June 1, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (US OTCQB: BVAXF)("BioVaxys" or "the Company") is pleased to announce that its bioproduction partner Bio Elpida of Lyon, France, has initiated construction of a new Good Manufacturing Prac...

2021-06-01 20:00 2700

Biovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor For Ovarian Cancer Vaccine Clinical Program And Papilocare Marketing

VANCOUVER, British Columbia, May 24, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, US OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce thatCharles J. Dunton, MD, has joined BioVaxys as an Advisor to help provide additional scientific support for BVX-0918A,...

2021-05-24 20:00 5318

BioVaxys Announces Appointment of Policy Advisor

VANCOUVER, BC, May 20, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:BVAXF)("BioVaxys"), a biotechnology company that is advancing viral and oncology vaccine platforms as well as immuno-diagnostic products, today announced the appointment ofAdam Coutts, PhD, as Policy ...

2021-05-20 20:00 10208

BioVaxys And BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine Bioproduction

VANCOUVER, BC, May 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (CSE: BIOV.CN) (FRA: 5LB) (OTC: BVAXF) ("BioVaxys" or "Company") announced today that it has signed the definitive exclusive bioproduction agreement ("Agreement") with BioElpida S.A.S. ("BioElpida") of Lyon,Franc...

2021-05-03 20:00 1837

BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH(R) Diagnostic

Commercial trademark application FILED for CoviDTH® diagnostic cancer vaccine platform patent coverageexpanded to NOW include over 12 tumor types VANCOUVER, B.C., April 29, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: BVAXF) ("BioVaxys" or "the Company"), the world ...

2021-04-29 20:56 1834